Sally Clive

1.3k total citations
30 papers, 500 citations indexed

About

Sally Clive is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Sally Clive has authored 30 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Cancer Research. Recurrent topics in Sally Clive's work include Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Sally Clive is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Sally Clive collaborates with scholars based in United Kingdom, United States and Spain. Sally Clive's co-authors include J. Gardiner, Renaud Léonard, Christopher J. Weir, J. Michael Dixon, Thomas Jaki, Mark Kagan, Margaret M. Woo, Michelle D. Sakala, Margaret Squier and Tanios Bekaii‐Saab and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Sally Clive

28 papers receiving 483 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sally Clive United Kingdom 13 190 178 76 62 58 30 500
Gautier Paux France 9 115 0.6× 41 0.2× 64 0.8× 50 0.8× 27 0.5× 26 394
Kyung Mann Kim United States 10 102 0.5× 110 0.6× 99 1.3× 25 0.4× 17 0.3× 16 363
John H. Moon United States 8 188 1.0× 147 0.8× 90 1.2× 40 0.6× 129 2.2× 12 574
Anja Henningsson Sweden 8 567 3.0× 197 1.1× 79 1.0× 69 1.1× 106 1.8× 12 889
Anshu Marathe United States 11 203 1.1× 183 1.0× 59 0.8× 55 0.9× 29 0.5× 22 559
Kehua Wu United States 11 210 1.1× 231 1.3× 22 0.3× 82 1.3× 20 0.3× 23 542
Mark Penney United Kingdom 15 75 0.4× 507 2.8× 46 0.6× 82 1.3× 61 1.1× 18 1.1k
Raja Velagapudi United States 13 79 0.4× 166 0.9× 28 0.4× 12 0.2× 118 2.0× 18 628
Yow‐Ming Wang United States 18 226 1.2× 350 2.0× 54 0.7× 20 0.3× 179 3.1× 54 1.0k
Agneta Freijs Sweden 8 249 1.3× 85 0.5× 25 0.3× 41 0.7× 36 0.6× 9 368

Countries citing papers authored by Sally Clive

Since Specialization
Citations

This map shows the geographic impact of Sally Clive's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sally Clive with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sally Clive more than expected).

Fields of papers citing papers by Sally Clive

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sally Clive. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sally Clive. The network helps show where Sally Clive may publish in the future.

Co-authorship network of co-authors of Sally Clive

This figure shows the co-authorship network connecting the top 25 collaborators of Sally Clive. A scholar is included among the top collaborators of Sally Clive based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sally Clive. Sally Clive is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Conway, Alicia‐Marie, Matthew Robinson, Matthew J. Concannon, et al.. (2024). CUPCOMP: A multi-site UK trial in carcinoma of unknown primary: A comparison across tissue and liquid biomarkers.. Journal of Clinical Oncology. 42(16_suppl). 3059–3059. 1 indexed citations
2.
Stares, Mark, Karin Purshouse, Gillian Knowles, et al.. (2021). Characterisation and outcomes of patients referred to a regional cancer of unknown primary team: a 10-year analysis. British Journal of Cancer. 125(11). 1503–1510. 7 indexed citations
3.
Stares, Mark, R. A. Patton, Gillian Knowles, et al.. (2020). A biobank analysis of prognostic biomarkers of the systemic inflammatory response in patients presenting with malignancy of undefined primary origin. European Journal of Cancer. 139. 1–9. 5 indexed citations
4.
Pallmann, Philip, Fang Wan, Adrian Mander, et al.. (2019). Designing and evaluating dose-escalation studies made easy: The MoDEsT web app. Clinical Trials. 17(2). 147–156. 7 indexed citations
5.
Woodcock, Victoria K., Sally Clive, Richard H. Wilson, et al.. (2018). A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. British Journal of Cancer. 118(6). 770–776. 10 indexed citations
6.
Love, Sharon, Sarah Brown, Christopher J. Weir, et al.. (2017). Embracing model-based designs for dose-finding trials. British Journal of Cancer. 117(3). 332–339. 44 indexed citations
7.
Slingerland, Marije, Dagmar Hess, Sally Clive, et al.. (2014). A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function. Cancer Chemotherapy and Pharmacology. 74(5). 1089–1098. 36 indexed citations
8.
Sémiond, Dorothée, et al.. (2014). A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors. Anti-Cancer Drugs. 26(3). 350–358. 13 indexed citations
9.
Capdevila, Jaume, Sally Clive, E. Casado, et al.. (2013). A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 71(5). 1247–1254. 7 indexed citations
10.
Jaki, Thomas, Sally Clive, & Christopher J. Weir. (2013). Principles of dose finding studies in cancer: a comparison of trial designs. Cancer Chemotherapy and Pharmacology. 71(5). 1107–1114. 39 indexed citations
11.
12.
Sémiond, Dorothée, et al.. (2012). Abstract 749: A Phase I, open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors. Cancer Research. 72(8_Supplement). 749–749. 2 indexed citations
13.
Faluyi, Olusola Olusesan, et al.. (2011). Accuracy of GFR estimation by the Cockroft and Gault, MDRD, and Wright equations in Oncology patients with renal impairment. Medical Oncology. 29(2). 755–760. 17 indexed citations
14.
Michie, Caroline O., et al.. (2010). The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study. British Journal of Cancer. 103(5). 617–621. 24 indexed citations
15.
Storey, D., Michelle D. Sakala, Catriona McLean, et al.. (2010). Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?. Annals of Oncology. 21(8). 1657–1661. 42 indexed citations
16.
Clive, Sally, et al.. (2009). Elucidation of the metabolic and elimination pathways of panobinostat (LBH589) using [14C]-panobinostat. Journal of Clinical Oncology. 27(15_suppl). 2549–2549. 8 indexed citations
17.
Capdevila, Jaume, Sally Clive, Josep Tabernero, et al.. (2009). Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma. Journal of Clinical Oncology. 27(15_suppl). 2568–2568. 4 indexed citations
18.
Clive, Sally & J. Michael Dixon. (2002). The Value of Adjuvant Treatment in Young Women with Breast Cancer. Drugs. 62(1). 1–11. 30 indexed citations
19.
Clive, Sally. (2001). Gastrin-releasing peptide is a potent vasodilator in humans. Clinical Pharmacology & Therapeutics. 69(4). 252–259. 13 indexed citations
20.
Clive, Sally, J. Gardiner, & Renaud Léonard. (1999). Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. Cancer Chemotherapy and Pharmacology. 44(0). S29–S30. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gautier Paux Breakdown of academic impact, for papers by Kyung Mann Kim Breakdown of academic impact, for papers by John H. Moon Breakdown of academic impact, for papers by Anja Henningsson Breakdown of academic impact, for papers by Anshu Marathe Breakdown of academic impact, for papers by Kehua Wu Breakdown of academic impact, for papers by Mark Penney Breakdown of academic impact, for papers by Raja Velagapudi Breakdown of academic impact, for papers by Yow‐Ming Wang Breakdown of academic impact, for papers by Agneta Freijs
Rankless by CCL
2026